全文获取类型
收费全文 | 530045篇 |
免费 | 27642篇 |
国内免费 | 496篇 |
专业分类
耳鼻咽喉 | 6681篇 |
儿科学 | 16923篇 |
妇产科学 | 12537篇 |
基础医学 | 92617篇 |
口腔科学 | 12347篇 |
临床医学 | 48501篇 |
内科学 | 95442篇 |
皮肤病学 | 11868篇 |
神经病学 | 34010篇 |
特种医学 | 19757篇 |
外国民族医学 | 53篇 |
外科学 | 78067篇 |
综合类 | 7612篇 |
现状与发展 | 2篇 |
一般理论 | 107篇 |
预防医学 | 38534篇 |
眼科学 | 11940篇 |
药学 | 41413篇 |
1篇 | |
中国医学 | 1134篇 |
肿瘤学 | 28637篇 |
出版年
2021年 | 3898篇 |
2018年 | 5733篇 |
2017年 | 4130篇 |
2016年 | 4872篇 |
2015年 | 5362篇 |
2014年 | 7114篇 |
2013年 | 10501篇 |
2012年 | 15575篇 |
2011年 | 17393篇 |
2010年 | 9956篇 |
2009年 | 8822篇 |
2008年 | 15710篇 |
2007年 | 17444篇 |
2006年 | 16939篇 |
2005年 | 16260篇 |
2004年 | 15882篇 |
2003年 | 15262篇 |
2002年 | 14783篇 |
2001年 | 22428篇 |
2000年 | 22970篇 |
1999年 | 18922篇 |
1998年 | 5233篇 |
1997年 | 4365篇 |
1996年 | 4397篇 |
1995年 | 4124篇 |
1992年 | 14414篇 |
1991年 | 15820篇 |
1990年 | 15951篇 |
1989年 | 15627篇 |
1988年 | 14308篇 |
1987年 | 14198篇 |
1986年 | 13168篇 |
1985年 | 12686篇 |
1984年 | 9394篇 |
1983年 | 8000篇 |
1982年 | 4178篇 |
1979年 | 8937篇 |
1978年 | 6382篇 |
1977年 | 5149篇 |
1976年 | 5505篇 |
1975年 | 6613篇 |
1974年 | 7419篇 |
1973年 | 7158篇 |
1972年 | 6597篇 |
1971年 | 6309篇 |
1970年 | 5887篇 |
1969年 | 5467篇 |
1968年 | 5161篇 |
1967年 | 4621篇 |
1966年 | 3964篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
81.
J. de Pedro-Cuesta V. Abraira G.-X. Jiang G. Solders S. Fredrikson 《Acta neurologica Scandinavica》1996,93(2-3):175-183
Using hierarchical cluster analysis, applied to 47 cases of Guillain-Barre Syndrome (GBS) incident in South-West Stockholm (SWS) during the period from January 1973 to June 1992, we identified three major clinicoepidemiological subgroups. The first subgroup, 25.5% of the cases (26.7 ± 6.7 years), recorded a peak incidence at ages 20–29 years and presented significant differences from other subgroups, a high proportion of cases with onset at low age preceded by respiratory infection (83.3%) and with normal motor conduction velocity (50.0%). Also found, were less affected biological parameters, a rapidly progressive course and independence in gait at one month after onset. A second subgroup, 27.7% of cases, was severely affected, clinically and functionally. It consisted predominantly of young individuals (22.7 ± 11.1 years), with a high incidence (69.2% of cases) in autumn. A third subgroup, comprising 40.47; of cases, was older (61.1 ± 11.0 years) and, in general, also severely affected. The incidence of this form appeared to be invariant with time. 相似文献
82.
83.
In experiments on albino rats it was established that three administrations of indomethacin in a dose of 0.01 g/kg body weight induced a severe damage of the liver characterized by disturbances of hepatocytic membranes, bile-producing and protein-producing functions of the liver, an enhancement of lipid peroxidation, a decrease of reduced glutathione pool. Antioxidants (tocopherol acetate, essentiale, legalon, flacumin) limit manifestations of indomethacin, hepatotoxicity, as a result of which tha functional-biochemical disorders in the liver show up to a lesser degree. During the combined use of antioxidants in indomethacin-induced lesions of the liver their hepatoprotective activity increases. 相似文献
84.
L R?stam R V Luepker M B Mittelmark D M Murray J S Slater H Blackburn 《American journal of preventive medicine》1988,4(5):249-254
To determine the potential effect of screening on referral patterns, an adult population sample (4,404 men, 5,164 women, 20-69 years of age) was systematically recruited and screened for hypercholesterolemia and then analyzed by different cholesterol referral recommendations. Using levels suggested by the Lipid Research Clinics Coronary Primary Prevention Trial (greater than or equal to 265 mg/dL), 7.3% of men and 5.8% of women would be referred for follow-up. With the suggested recommendations of the National Cholesterol Education Program (NCEP), (greater than or equal to 200 mg/dL), 49.2% of men and 40.2% of women would be referred. The use of age-related definitions of the NIH Consensus Conference on Lipid Lowering results in 28.0% referrals in men and 21.8% in women. From this population, hypercholesterolemia subjects (greater than or equal to 265 mg/dL at screening; n = 624) were invited for a second cholesterol determination (58% returned), which found 36% below the 265 mg/dL level. Population screening for cholesterol is likely to produce large numbers of patients for follow-up, with the actual numbers strongly dependent on cutoff levels and age-sex distributions. Referral and follow-up of these patients may place a significant load on an unprepared health care community. 相似文献
85.
86.
87.
88.
A. Giacometti O. Cirioni G. Greganti A. Fineo R. Ghiselli M. Del Prete F. Mocchegiani B. Fileni F. Caselli E. Petrelli V. Saba G. Scalise 《European journal of clinical microbiology & infectious diseases》2002,21(7):553-556
The in vitro activities of povidone iodine, potassium peroxymonosulfate, and dimethyldidecylammonium chloride were investigated
against 379 nosocomial isolates of Staphylococcus aureus and Pseudomonas aeruginosa responsible for surgical wound infections in patients operated on between July 1995 and June 2001. Overall, the isolates
were inhibited by the antiseptics at concentrations below those used routinely. In spite of increasing resistance to the various
antibiotics used to treat surgical wound infections, no significant variation in the susceptibility to antiseptics was demonstrated
during this 6-year study.
Electronic Publication 相似文献
89.
90.
Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study 总被引:1,自引:0,他引:1
M. J. V?lim?ki K. Laitinen K. Laitinen A. Patronen H. Puolijoki H. Puolijoki J. Sepp?nen L. Pylkk?nenand the Probone Study Group 《Osteoporosis international》2002,13(12):937-947
This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the
prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53
years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was
at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800
mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days
for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of
2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg
of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening,
and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were
−3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to
4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference
between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5%
in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between
groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral
neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between
clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate
in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually
within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose
of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively
reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective,
placebo-controlled trials.
Received: 4 March 2002 / Accepted: 9 July 2002 相似文献